Science

Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs…

Among 3813 PWUD at baseline, 1093 (29%) reported daily use of illicit opioids and 229 (6%) reported psychedelic use in the past six months. Over study follow-up after adjusting for a range of potential confounders, psychedelic use remained independently associated with a significantly reduced odds of subsequent daily opioid use (Adjusted Odds Ratio: 0.45; 95%…

READ MORE
Science

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers

This examination of a large international sample of adults highlights the prominence of therapeutic and wellness motivations for microdosing psychedelic drugs and identified lower levels of anxiety and depression among microdosers relative to controls.  Comparisons of psilocybin to LSD microdosers indicated no differences on measures of Depression, Anxiety and Stress from the DASS-21 (all values for F (1, 827) < 1.0, p > 0.50). The inclusion of…

READ MORE
Science

Using marijuana with psychedelics intensifies the mystical experience, study finds

Researchers at Imperial College London [report]… Use of cannabis together with psychedelics was “associated with higher scores of mystical-type experience, ego-dissolution and visual alterations,” the study, published last week in the journal Psychopharmacology, states. And in general, the more marijuana a person said they used, the more intense the psychedelic effect… there was a unique…

READ MORE
Science

…analog… psilocybin

…[ie] deuterated psilocybin analog has a duration of effect that is half is long as psilocybin, and a duration onset that is twice as fast. …[research pipeline seeking & developing] drugs with less variability [with goals such as] a faster onset time and better brain penetration that maintain the therapeutic properties of psilocybin and deliver…

READ MORE
Science

Compass pathways’ phase 2B… breakthrough therapy designation by the US FDA in late 2018… delivers mixed results

…a 35-percent response rate and a 5-percent SAE rate means for every seven patients positively responding to the treatment, one person will experience serious negative outcomes… these serious adverse events included suicidal ideation and suicidal behavior. Five patients (6.3 percent) in the 25-mg group and six patients (8 percent) in the 10-mg group experienced at…

READ MORE
Science

FDA approves first clinical trial using naturally sourced psychedelics

With… propriety technology… stable formulations of both psilocin and psilocybin from magic mushrooms.  …drug development efforts are focused exclusively on extracting, purifying, and standardizing natural psychedelic compounds. Original Article (Psychedelic Spotlight):FDA approves first clinical trial using naturally sourced psychedelicsArtwork Fair Use: Perdula

READ MORE
Science

More evidence of the chemical compound variability in magic mushrooms

…the variability of compounds in magic mushrooms… environmental variables such as light and the type of growing medium influence the presence and amount of certain compounds… in the mushroom fruiting bodies… …isolated and tested for multiple compounds of interest in the mushroom including the tryptamine alkaloids: baeocystin, norbaeocystin, norpsilocin, aeruginascin, 4-HO-TMT, 4-hydroxytryptamine. The beta-carbolines: harmine, harmane, norharmane, harmol. Original Article (Psychedelic Science…

READ MORE
Science

Salvia divinorum [&] analgesic & anti-inflammatory action

…the minutes-long hallucinogenic and dissociative effects of recreational S. divinorum in humans have been described in detail. Salvia divinorum… inhibited contractions of the mouse colon, stomach, and ileum in vitro; prolonged colonic propulsion; and slowed upper GI transit in vivo by activating KOR, CB1, and interestingly by activating cannabinoid type 2 receptors (CB2). In our laboratory, we…

READ MORE
Science

Shrooms and lsd linked to lower heart disease and diabetes risk

“The findings suggest that lifetime classic psychedelic use is associated with lower odds of having had heart disease or diabetes in the past year,” lead study author and Oxford sociologist Otto Simonsson, [said]. A team of scientists identified the unexpected trend after poring over ten years’ worth of data from the National Survey on Drug…

READ MORE